Overview

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the ASCEND clinical trial is to measure the effect of adding CEND-1, compared to placebo, to chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. The study will assess the duration which the cancer remained stable or improved, the number of patients who responded to treatment, overall survival, side effects and quality of life.

Phase:

Phase 2

Details

Lead Sponsor:

University of Sydney

Collaborator:

Australasian Gastro-Intestinal Trials Group

Treatments:

Gemcitabine
Paclitaxel